ArticleNpj viruses2026
COVID-19 boosters restore virus-specific immune responses in kidney transplant recipients unresponsive to primary vaccination.
Article in Npj viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Kidney transplant recipients (KTRs) often exhibit impaired immune responses to vaccination, necessitating multiple doses to obtain sufficient protection from severe disease. This study compared immunological mechanisms underlying the vaccine-induced response between KTRs who responded to primary vaccination (primary responders) and those who only responded to a booster vaccination (booster responders). Humoral immune responses, including binding and Fc-mediated functionalities, and T cell responses, were generally comparable in primary and booster responders. More in-depth analyses revealed that booster responders had an expanded memory B cell pool and stronger omicron BA.1 neutralization, while primary responders had more IL-21-producing T cells and a distinct SARS-CoV-2-specific CD4 T cell phenotype. Principal component analysis demonstrated that booster responders exhibited a more refined immune network integration. These results suggest that the delayed immune response of booster responders is not functionally impaired and that repeated vaccination is an effective strategy to achieve adequate protection in this population.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.